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Background-—Regression of left ventricular (LV) hypertrophy (LVH) has been a goal in clinical trials. This study tests the external
validity of results of clinical trials on LVH regression using a large registry from a tertiary care center, to identify phenotypes less
likely to achieve regression of LVH.
Methods and Results-—Patients from the Campania Salute Network, free of prevalent cardiovascular disease, but with
echocardiographic LVH (deﬁned as LV mass index [LVMi] >47 g/m2.7 in women and >50 g/m2.7 in men) were included.
During a median follow-up of 67 months, clear-cut regression of LVH was documented in 14% of patients (138% reduction
of initial LVMi) or 23% when also considering those with a reduction of LVMi ≥5 g/m2.7. Patients with persistent LVH were
older with longer duration of hypertension, suboptimal blood pressure (BP) control, larger body mass index, LV mass, and
carotid intima-media thickness and included more women and subjects with diabetes mellitus, isolated systolic
hypertension, and metabolic syndrome (all P<0.05). Number and class of antihypertensive drugs during follow-up did not
differ between groups. In multiple logistic regression analysis, older age, female sex, obesity, higher baseline LVMi and
carotid intima-media thickness, and suboptimal BP control were signiﬁcant covariates of persistent LVH (all P≤0.01),
independent of diabetes, duration of hypertension, isolated systolic hypertension, follow-up time and number and class of
antihypertensive drugs.
Conclusions-—Early initiation of antihypertensive treatment, aggressive BP control, and attention to metabolic aspects are critical
to avoid irreversible LVH. ( J Am Heart Assoc. 2017;6:e004152. DOI: 10.1161/JAHA.116.004152.)
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L eft ventricular (LV) hypertrophy (LVH) is a risk predictorin hypertension,1,2 and clinical trials have demonstrated
that LVH regression during antihypertensive treatment
reduces cardiovascular morbidity and mortality.3–5 Thus,
LVH regression is considered a therapeutic target and a
reversible risk marker in hypertension.6 Some studies indicate
that different classes of antihypertensive medication might
differ in their ability to promote LVH regression.7,8 However,
most interesting, a number of studies have demonstrated that
LVH regression is not always achieved, even when blood
pressure (BP) is optimally controlled, in particular, in women
and obese subjects.9–11 Recently, results from the Strong
Heart Study, a population-based cohort, including hyperten-
sive patients with multiple cardiovascular risk factors and
comorbidities, demonstrated an average increase in LV mass
(LVM) during follow-up, even in the subpopulation with
optimal BP control.11 These ﬁndings suggest that in the real
world, there might be problems in achieving effective LVH
regression, which are not explored in clinical trials that are
conducted in selected hypertensive populations.12
Accordingly, we analyzed a large series of treated hyper-
tensive outpatients with established LVH from a tertiary care
center, to test the external validity of the results of clinical
trials on LVH regression and identify the clinical phenotypes
less likely to achieve LVH regression during antihypertensive
treatment.
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Methods
Study Population
The Campania Salute Network (CSN) is an open registry
collecting information from general practitioners and commu-
nity hospitals networked with the Hypertension Center of the
Federico II University Hospital (Naples, Italy).13 Characteris-
tics of the registry have been previously reported in detail.14
Brieﬂy, the database generation was approved by the Federico
II University Hospital Ethic Committee and signed informed
consent to use data for scientiﬁc purposes was obtained from
all participants. At the time of the present analysis, 14 055
hypertensive patients aged ≥18 years were registered in the
CSN. After excluding patients with prevalent cardiovascular
disease (n=3531), less than 24 months of follow-up
(n=4729), and patients without LVH at baseline (n=3622),
the ﬁnal study population consisted of 2173 hypertensive
patients with ascertained LVH at the ﬁrst echocardiogram
performed at the time of the ﬁrst visit, at the enrollment into
the registry.
Clinical and Laboratory Examinations
Systolic (SBP) and diastolic BP (DBP) were measured in the
sitting position by a calibrated aneroid sphygmomanometer
after 5 minutes of resting. Consistent with the current
guidelines,6 BP was measured 3 times at 2-minute intervals
and the average of the last 2 BP was taken as the ofﬁce BP.
Isolated systolic hypertension (ISH) was deﬁned as baseline
SBP ≥140 mm Hg and baseline DBP <90 mm Hg. BP was
considered optimally controlled when ofﬁce SBP was, on
average, <140 mm Hg and DBP, on average, <90 mm Hg as
the mean of measurements in the control visits during the
follow-up.
Fasting lipid and glucose proﬁle was measured by standard
methods. Body mass index (BMI) was calculated as body
weight divided by height in squared meters, and obesity was
deﬁned as BMI ≥30 kg/m2. Metabolic syndrome (MetS) was
deﬁned according to the modiﬁed ATPIII criteria,15 substitut-
ing waist circumference with BMI ≥30 kg/m2, as previously
done when waist circumference was not available.16,17
Glomerular ﬁltration rate (GFR) was estimated using the
simpliﬁed Modiﬁcation of Diet in Renal Disease formula.18
Antihypertensive Medication
Number and type of prescribed antihypertensive medication
were recorded for all participants during initial and control
visits. Classes of medications included anti-renin–angiotensin
system medications (angiotensin-converting enzyme [ACE]
inhibitors and/or angiotensin AT1 receptor blockers [ARB]),
calcium (Ca)-channel blockers (CCBs), beta-blockers, and
diuretics. All classes were considered according to their
overall use during the individual follow-up, based on the
frequency of prescription during the control visits (every
4 months–1 year interval). As previously reported,19,20 all
medications that were prescribed in more than 50% of the
follow-up visits were considered in the analysis as part of the
treatment in the individual patient.
Echocardiography
Echocardiograms were performed at the time of the initial
visit in the Hypertension Center and at the follow-up visits
using commercially available machines by a standardized
protocol. Patients underwent a number of echocardiograms
during follow-up (at least once a year). Quality-controlled
validation was performed for echocardiographic exams per-
formed at the enrollment in the registry (baseline), at the last
available echocardiogram before a censored event, or at the
time of the last available visit before the present database
generation. As previously reported,21,22 echocardiograms
were recorded on videotapes, stored digitally, and read ofﬂine
by 1 expert reader under the supervision of a senior faculty
member on dedicated workstations (MediMatic, Genova,
Italy). Measurements were made according to the joint
American Society of Echocardiography/European Association
of Echocardiography recommendations.23 LVM was calcu-
lated from a necropsy-validated formula24 and indexed for
height in meters to the power of 2.7 (LV mass index; LVMi).25
Relative wall thickness was computed as posterior wall
thickness/LV end-diastolic radius, and concentric LV geom-
etry was deﬁned as relative wall thickness ≥0.43.26 Regres-
sion of LVH was adjudicated when LVMi was <50 g/m2.7 in
men and <47 g/m2.7 in women27 at the time of the last
available visit of the follow-up. Alternative analyses were run
pooling patients with follow-up LVMi reduction of at least
5 g/m2.7 with those normalizing LVMi.
Arterial stiffness was estimated as the ratio between
brachial pulse pressure and stroke index, as previously
reported.28
Carotid Ultrasound
Carotid ultrasound was performed as previously reported.29
Brieﬂy, patients were accommodated in the supine position
with the neck extended in mild rotation. The scanning
protocol was performed with an ultrasound device (SONOS
2500/5500; HP, Philips, Best, The Netherlands) equipped
with a 7.5-MHz high-resolution transducer with an axial
resolution of 0.1 mm. Examinations were recorded on S-VHS
videotapes and analyzed ofﬂine using an image-processing
dedicated workstation (MediMatic). The maximal arterial
intima-media thickness (IMT) was estimated in up to 12
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arterial walls, including the right and the left, near and far
distal common carotid, bifurcation, and proximal internal
carotid artery as previously described in detail.29
Statistical Analysis
Data were analyzed using SPSS software (version 22.0; SPSS,
Inc., Chicago, IL) and continuous variables are reported as
mean1 SD or by median and interquartile range (IQR), for
variables deviating from normal distribution, whereas cate-
gorical variables were reported as percentages. Descriptive
statistics are presented in patients with or without LVH
regression, using t test and chi-squared statistics, as appro-
priate. For skewed variables, the nonparametric Mann–
Whitney U test was used.
Univariate logistic regression was used to identify signiﬁcant
association with lack of LVH regression. Forward step-wise
multivariable logistic regression analysis, including covariates
identiﬁed in univariate logistic analysis, was used to identify
independent factors associated with lack of regression of LVH.
In a second model, we also forced in the number of antihyper-
tensive drugs and single classes of medications. The same
procedure was adopted for the other criterion (including
reduction of at least 5 g/m2.7 or normalization of LVMi).
Cox regression analysis was used to assess whether lack
of LVH regression was associated with higher risk of incident
cardiovascular events (fatal and nonfatal myocardial infarc-
tion, stroke and heart failure, angina, transient ischemic
attack, myocardial or carotid revascularization, and atrial
ﬁbrillation). The same analysis was also performed consider-
ing normalization or ≥5 g/m2.7 reduction of initial LVMi.
Assessment of LVMi was done at the time of either the last
available echocardiogram or the echocardiogram immediately
preceding the occurrence of the ﬁrst cardiovascular event.
Results
Prevalence and Prognostic Impact of LVH
Regression
The study population consisted of 2173 hypertensive patients
with mean age 5710 years and 48% were women. During a
median follow-up of 7.0 (IQR, 5.0–12.0) years, LVH regression
was achieved in 295 patients (14%), though optimal BP was
achieved in 1898 (87%). Considering also a reduction of initial
LVMi ≤5 g/m2.7, the proportion of patients with signiﬁcant
reduction of LVMi increased to 489 (ie, 23%). In the total study
population, follow-up reduction in SBP was917 mm Hg, in
DBPwas610 mm Hg, and in LVMiwas9.110.8 g/m2.7.
Patients with LVH regression had amean reduction of 138% in
LVMi compared to a slight increase of 210% in LVMi in the
group of participants without LVH regression (P<0.001).
During follow-up, a total of 185 cardiovascular events
occurred. In Cox regression analysis, adjusting for age and
sex, lack of LVH regression was associated with higher hazard
rate of cardiovascular events (hazard ratio [HR], 1.71 [95% CI
1.05–2.78]; P=0.03). Similarly, in the alternative analysis, lack
of either reduction or normalization of LVMi was associated
with increased hazard of cardiovascular events (HR, 1.56 [95%
CI 1.06–2.28]; P=0.02).
Clinical Phenotypes of Patients With Lack of LVH
Regression
Patients who did not experience LVH regression were older,
had longer duration of hypertension, higher baseline SBP and
BMI, and included more women and subjects with diabetes
mellitus, obesity, ISH, and MetS (all P≤0.001; Table 1).
Smoking habit was less frequent and follow-up time shorter
among patients who did not achieve regression of LVH
(P<0.04; Table 1). There were no signiﬁcant differences in
DBP, heart rate, and lipid proﬁle. Follow-up time was longer in
patients with regression of LVH (P=0.003; Table 1). Similar
results were obtained when pooling patients with reduction in
LVMi <5 g/m2.7 with those with persistent LVH (Table S1).
Lack of LVH regression was associated with greater LVMi
and carotid IMT (P<0.01; Table 1) as well as lower GFR at
baseline (P<0.05; Table 2). There was no signiﬁcant differ-
ence in relative wall thickness and proportion of concentric LV
geometry at baseline (Table 2). In contrast, pooled patients
without either reduction or normalization of LVMi exhibited
higher carotid IMT, lower LVMi at baseline, and less-common
concentric LV geometry (Table S2). At follow-up, concentric
geometry was signiﬁcantly more common among patients
with lack of LVH regression (Table 2) or those without either
reduction or normalization of LVMi (Table S2). Average
baseline arterial stiffness did not differ between patients
without or with LVH regression (Table 2), whereas it was
higher when also considering patients without signiﬁcant
reduction of LVMi (Table S2).
Less reduction in both SBP and DBP during follow-up and
less optimal BP control were observed in patients with lack of
regression of LVH (Table 3), and in those without either
reduction or normalization of LVMi (Table S3), though the
number and types of antihypertensive medication did not
differ signiﬁcantly between these groups, except for beta-
blocker being more common in patients without reduction or
normalization of LVMi.
Covariates of Lack of LVH Regression
In logistic regression analysis, older age, female sex, obesity,
lack of BP control, less reduction of systolic BP during follow-
up, and higher baseline LVMi and carotid IMT were
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independently associated with lack of LVH regression. These
associations were independent of diabetes mellitus, duration
of hypertension, presence of ISH, follow-up duration (all
variables that were signiﬁcant in univariate analysis), and also
independent of number and class of antihypertensive medi-
cation (Table 4). In the same model of analysis, the indepen-
dent signiﬁcant covariates of lack of either reduction or
normalization of LVMi were older age, female sex, obesity,
ISH, lack of BP control, less reduction in SBP during follow-up,
lower baseline LVMi, higher carotid IMT, and less-frequent
prescription of beta-blocker (Table S4).
Discussion
This study demonstrates that clear-cut LVH regression was
infrequently achieved in the CSN registry, a tertiary care
Table 1. Clinical Characteristics of the Study Participants
With or Without Regression of LVH During Follow-up
Variables
No LVH
Regression
(N=1878)
LVH
Regression
(n=295) P Value
Age, y 5810 5410 <0.0001
Women, % 50 36 <0.0001
Duration of
hypertension, y
8.17.6 6.37.6 <0.0001
BMI, kg/m2 29.64.4 27.93.5 <0.0001
Obesity (BMI ≥30
kg/m2), %
42 24 <0.0001
Isolated systolic
hypertension
baseline, %
20 14 0.021
Diabetes mellitus, % 15 9 0.019
MetS, % 39 26 <0.0001
Smoking, % 15 21 0.032
Systolic BP baseline,
mm Hg
14920 14621 0.015
Diastolic BP baseline,
mm Hg
9012 9112 0.411
Mean follow-up
systolic BP, mm Hg
14013 13511 <0.0001
Mean follow-up
diastolic BP, mm Hg
847 836 0.031
Heart rate baseline,
bpm
7311 7412 0.296
Total-cholesterol,
mg/dL
20639 20237 0.126
LDL-cholesterol,
mg/dL
12836 12533 0.113
Triglycerids, mg/dL 14176 13775 0.369
Follow-up time, y 5.4 (3.2–9.3) 6.5 (4.1–9.9) <0.001
No. of visits per patient 7.0 (5.0–12.0) 8.0 (5.0–12.0) 0.098
No. of visits per patient
year
1.3 (1.1–1.8) 1.3 (1.1–1.5) <0.001
No. of echocardio-
grams
3 (2–5) 4 (3–5) <0.001
BMI indicates body mass index; BP, blood pressure; LDL, low-density lipoprotein; LVH,
left ventricular hypertrophy; MetS, metabolic syndrome.
Table 2. Cardiac and Vascular Structural Characteristics of
the Study Participants With or Without Regression of LVH
During Follow-up
Variables
No LVH
Regression
(N=1878)
LVH
Regression
(n=295) P Value
Carotid IMT max 1, mm 1.80.8 1.60.7 <0.0001
LV mass index baseline, g/
m2.7
56.87.7 52.74.9 <0.0001
Concentric baseline LV
geometry, %
16 19 0.171
Concentric follow-up LV
geometry, %
14 6 <0.001
e-GFR, mL/min per 1.73 m2 7317 7517 0.048
Pulse pressure/stroke index,
mm Hg/mL9m2.04
2.120.63 2.090.57 0.401
e-GFR indicates estimated glomerular ﬁltration rate; IMT, intima media thickness; LV, left
ventricular; LVH, left ventricular hypertrophy; max, maximum.
Table 3. Blood Pressure and Distribution of Antihypertensive
Medication Among Patients With or Without Regression of
LVH During Follow-up
Medication
No LVH
Regression
(N=1878)
LVH
Regression
(n=295) P Value
Reduction in SBP during
follow-up, mm Hg
917 1117 0.019
Reduction in DBP during
follow-up, mm Hg
610 810 0.015
Optimal BP control
baseline, %
51 47 0.436
Optimal BP control
during follow-up, %
87 92 0.007
No. of antihypertensive
drugs
1.91.0 1.81.0 0.057
Beta-blocker, % 28 24 0.143
Ca-channel blockers, % 32 28 0.155
ACE inhibitors, % 42 36 0.062
ARB, % 35 40 0.129
Diuretics, % 54 52 0.508
ACE indicates angiotensin converting enzyme; ARB, angiotensin AT1 receptor blocker;
BP, blood pressure; Ca, calcium; DBP, diastolic blood pressure; LVH, left ventricular
hypertrophy; SBP, systolic blood pressure.
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center for arterial hypertension, despite an overall good BP
control. LVH regression was found only in 14% of hypertensive
outpatients with LVH at baseline, followed for a median of
67 months, and this proportion raised to only 23% when
considering also patients remaining with LVH but reducing
their initial LVMi of at least 5 g/m2.7.
The phenotype of the hypertensive patient who did not
experience LVH regression was typically an old, obese
woman, with suboptimal systolic BP control over time,
established vascular damage, and higher values of LVMi,
reﬂecting high cardiovascular risk. No independent associa-
tions were found with diabetes mellitus, ISH, reported
duration of hypertension, and number and types of antihy-
pertensive medications. In patients with severe LVH, a
signiﬁcant reduction of LVMi can occur without necessarily
achieving normal values. This was the reason to perform a
secondary analysis displayed in the appendix, accounting also
for a signiﬁcant reduction (≥5 g/m2.7) in LVMi. Both analyses
indicate that reduction of LVMi or normalization of LVH is
more difﬁcult to achieve in old females with high cardiovas-
cular risk and poor BP control, but also that the lack of
regression of LVH or lack of signiﬁcant reduction in LVMi
exposes patients to higher cardiovascular risk.
The low proportion of LVH regression in hypertensive
patients from the CSN registry is in line with results from a
randomized, clinical trial, the Losartan Intervention For
Endpoint Reduction in Hypertension (LIFE) study,9 demon-
strating lack of LVH regression in subgroups of hypertensive
patients with MetS. In addition, lack of LVH regression despite
BP control was also demonstrated in an unselected popula-
tion-based cohort with high prevalence of obesity and
diabetes mellitus.11 The negative independent impact of
female sex on LVH regression, shown in Table 4, is also
consistent with previous results demonstrating less LVH
regression in elderly women, and in patients with diabetes
mellitus, obesity, and other metabolic disturbances, all
independent of BP control.9,10,30
In exploratory analysis, ISH was more common in hyper-
tensive patients with lack of LVH regression, supporting a
previous ﬁnding from the LIFE study.31 However, after
controlling for critical covariates (obesity and BP control
during treatment), the negative effect of uncontrolled BP on
Table 4. Uni- and Multivariable Regression Analysis of Covariates Associated With Lack of LVH Regression in Treated
Hypertensive Subjects
Univariable
Multivariable
Model 1 Model 2
OR 95% CI P Value OR 95% CI P Value OR 95% CI P Value
Age, y 1.04 1.03 to 1.05 <0.001* 1.03 1.02 to 1.05 <0.001 1.03 1.02 to 1.05 <0.001
Female sex 1.73 1.35 to 2.24 <0.001* 2.55 1.88 to 3.45 <0.001 2.65 1.94 to 3.62 <0.001
BP control (n/y) 0.55 0.35 to 0.85 0.008* 0.52 0.32 to 0.87 0.012 0.52 0.31 to 0.86 0.011
LVMi, g/m2.7 1.13 1.10 to 1.16 <0.001* 1.16 1.12 to 1.20 <0.001 1.16 1.12 to 1.20 <0.001
Obesity (n/y) 2.25 1.69 to 2.98 <0.001* 1.98 1.45 to 2.70 <0.001 2.06 1.51 to 2.82 <0.001
Carotid IMT, mm 1.55 1.29 to 1.86 <0.001* 1.28 1.03 to 1.59 0.028 1.28 1.02 to 1.59 0.032
Diabetes mellitus (n/y) 1.61 1.08 to 2.42 0.020*
Isolated systolic hypertension (n/y) 1.51 1.06 to 2.13 0.022*
Duration of hypertension, y 1.04 1.02 to 1.06 <0.001*
No. of antihypertensive drugs 1.12 0.99 to 1.00 0.075 0.88 0.62 to 1.25 0.477
Follow-up time, y 0.96 0.93 to 0.99 0.004
Reduction in SBP (5 mm Hg) 0.95 0.90 to 0.99 0.015* 0.93 0.89 to 0.99 0.014 0.93 0.89 to 0.99 0.015
Reduction in DBP (5 mm Hg) 0.90 0.83 to 0.98 0.013*
Beta-blocker 1.24 0.93 to 1.65 0.144 0.70 0.45 to 1.09 0.114
Ca-channel blockers 1.22 0.93 to 1.60 0.155 0.75 0.48 to 1.17 0.204
ACE inhibitors 1.27 0.99 to 1.64 0.062 0.85 0.61 to 1.17 0.312
ARB 0.82 0.64 to 1.06 0.130 1.14 0.70 to 1.62 0.477
Diuretics 1.09 0.85 to 1.34 0.508 1.21 0.73 to 2.02 0.456
*Model 1: including variables that were signiﬁcant in univariable logistic analysis.
Model 2: also including number and class of medication forced into the Model 1. ACE indicates angiotensin converting enzyme; ARB, angiotensin AT1 receptor blocker; BP, blood pressure;
Ca, calcium; DBP, diastolic blood pressure; LVH, left ventricular hypertrophy; LVMi, LV mass index; OR, odds ratio; SBP, systolic blood pressure.
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the possibility of LVH regression emerged as the key reason
of lack of regression, being very common in patients with
ISH.32,33
The disappointing low rate of LVH regression in the CSN
registry is in apparent contrast with previous ﬁndings from a
number of randomized, clinical trials in arterial hypertension,
in which treatment induced a substantial reduction of
LVM.7,34,35 For instance, previous clinical trials have demon-
strated echocardiographic LVH regression in 50% to 60% of
hypertensive patients with LVH during antihypertensive
treatment.4,36 The relatively low reduction in BP achieved
during antihypertensive treatment may also partly explain the
observed low rate of LVH regression. Analysis performed in
the Strong Heart Study, a population-based cohort, showed
similar ﬁndings also in the context of target BP control.11
Among the Strong Heart Study participants with baseline LVH,
85% remained with LVH (deﬁned in that study as reduction of
5% of the initial value) at the follow-up, compared to the 15%
who exhibited reduction of the initial LVMi (P<0.0001). A
meta-analysis of 4 clinical trials assessing echocardiographic
regression of LVH reported only 8% LVH regression.37
The fact that LVH regression demonstrated in placebo-
controlled, randomized, clinical trials and several meta-
analyses could not be conﬁrmed in our analysis of hyperten-
sive patients from a large, real-word registry collected in a
tertiary care center could be expected. The selection imposed
in clinical trials and meta-analyses remains an important
problem when transferred to the real world in patients with
characteristics and risk proﬁle that do not reﬂect the trial
selection.12 The CSN registry recruits from a number of
hypertensive outpatient clinics treating patients with a variety
of clinical presentations, including a number of associated
conditions that would not fulﬁll the selection criteria required
by the major trials. The patient selection is of critical
importance to try weighting for major confounders, but the
majority of hypertensive patients seen in routine clinical
practice would not be eligible for randomized, controlled
trials.38 Thus, the results of clinical trials, which have strong
internal validity, are suggested to be tested for external
validity in observational studies.12
Another important characteristic of outpatients in a tertiary
care center is their clinical history. Unlike patients included in
many clinical trials who often had short duration of hyper-
tension and were untreated, the CSN patients have, on
average, 8 years duration of hypertension and, especially
important, they come to the outpatient clinic of the Hyper-
tension Center of the Federico II University Hospital after
variable periods and cycles of antihypertensive treatment.
Thus, in this context, hypertensive LVH reﬂects consolidated
organ damage possibly resistant to previous therapy, though
often the prescribed therapy before admission to our
hypertension center was not effective for optimal BP
reduction. However, of course, we cannot determine how
many patients could have had their LVMi signiﬁcantly reduced
before their ﬁrst contact with our hypertension center.
Overall, results from registries are important to derive
more realistic expectations on treatment effect, and to
identify the characteristics of high risk individuals in a setting
closer to clinical practice in the real world.12
Our ﬁndings also indirectly conﬁrm that BP and target
organ damage control are better achieved when arterial
hypertension is managed at an early stage and in the absence
of other metabolic abnormalities,32,39 whereas antihyperten-
sive therapy is less effective when the disease has progressed
toward more-advanced stages.40
Whether and how much metabolic, nonhemodynamic
stimuli participate in the development of irreversible myocar-
dial structural changes cannot be explored in this type of
study, but some inference can be attempted. Increase in LVM
and consequent development of LVH is a process not
exclusively related to sarcomere-dependent cardiomyocyte
hypertrophy, especially in obese individuals, in whom other
cellular and structural components, including extracellular
matrix, ﬁbroblasts, adipocytes, as well as increase in
cardiomyocyte size attributed to fat inﬁltration, are
involved.41–43 Thus, BP control alone may not be sufﬁcient
to induce regression of LVH when other metabolic factors also
inﬂuence LV geometry.44 Among them, visceral fat might have
particular importance. In a subpopulation of individuals with
severe alteration of body composition and substantial excess
of body fat associated with relative fat-free mass deﬁciency,
often referred to as “sarcopenic obesity,” paradoxically LVM is
increased and LV geometry is concentric, independent of BP
values, suggesting that in these subjects modiﬁcation of LV
geometry are not induced by hemodynamic factors.45 It is
also interesting that sarcopenic obesity is a speciﬁc charac-
teristic of obese women.45
Study Limitations
As noticed above, this is an observational study including
hypertensive patients enrolled in a large, open, outpatient
registry; consequently, the follow-up time for the individual
patients differs. To account for the potential bias introduced
by the difference in follow-up time, we included follow-up time
in the multivariable models, because time-varying echocar-
diographic analysis of LVMi could not be run. In addition, we
only included patients with at least 24 months of follow-up,
because we know from previous randomized, clinical trials
that LVH regression mainly occurs during the ﬁrst 24 months
of follow-up.7,9 In addition, observational studies are, in
general, well suited to identify predictors in real-word
contexts, which was the aim of our study. In particular, one
of the advantages of observational studies compared to
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controlled studies is the generation of results into a real-world
context, which allows generalization and provides external
validation for clinical trials.12
Classiﬁcation and reclassiﬁcation of LVH by echocardio-
graphy, based on single assessments, might be challenging,
because of the intrinsic noise in the measurement.
However, echocardiographic assessment of LVM has previ-
ously been demonstrated to maintain sufﬁcient reliability to
be used in clinical practice. In the RES study, we found that
test-retest changes in LVMi of around 10% in single
patients have a reasonable chance to exceed the possible
technical error and, in highly skilled contexts, have clinical
relevance.46
Conclusion
LVH regression occurred in 14% of treated hypertensive
patients with initial LVH during follow-up. Patients who
experienced lack of LVH regression during antihypertensive
treatment were older, more often female with more end-
organ damage, and suboptimal BP control and exhibited an
increased risk of cardiovascular events. Development and
maintenance of hypertensive LVH is multifactorial and partly
independent of BP, in particular, in hypertensive patient
with obesity and/or clustering of cardiovascular risk
factors, indicating that management of arterial hypertension
cannot be limited to BP control, as already suggested by
guidelines.6 Eventually, there is the need to implement
speciﬁc studies on women who seem to be particularly
exposed.
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Table S1. Clinical characteristics of the study participants without or with ≥5 g/m2.7 regression 
of LVMi or normalization of LVMi during follow-up 
Variables No LVMi 
reduction 
(N = 1684) 
LVMi 
reduction 
(N = 489) 
P-
value 
Age (years) 58±10 55±11 <0.001 
Women (%) 50 39 <0.001 
Duration of HT (years) 8.1 ±7.6 7.0± 7.6 0.006 
BMI (kg/m2) 29.5±4.4 28.7±4.1 <0.001 
Obesity (BMI ≥ 30 kg/m2) (%) 41 32 <0.001 
Isolated systolic HT baseline (%) 20 13 <0.001 
Diabetes (%) 16 11 0.028 
Metabolic Syndrome (%) 39 32 0.014 
Smoking (%) 14 19 0.055 
Systolic BP baseline (mmHg) 149± 19 148 ±21 0.609 
Diastolic BP baseline (mmHg) 90±12 92±12 0.004 
Mean follow-up systolic BP (mmHg) 141±13 137±12 <0.001 
Mean follow-up diastolic BP (mmHg) 84±7 84±7 0.378 
Heart rate baseline (bpm) 73±11 74±12 0.691 
Total-Cholesterol (mg/dL) 206±39 201±37 0.013 
LDL-cholesterol (mg/dL) 129±37 125±33 0.021 
Triglycerids (mg/dL) 141±75 137±77 0.286 
Follow-up time (years) 5.4 (3.2-9.2) 6.3 (3.6-9.7) 0.002 
Number of visits pr patient 7.0 (5.0-12.0) 8.0 (5.0-13.0) 0.011 
Number of visits pr patient year 1.3 (1.1-1.8) 1.3 (1.1-1.6) 0.080 
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Number of echocardiograms 3 (2-5) 4 (3-5) <0.001 
HT: Hypertension; BMI: Body mass index; BP: Blood pressure.
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Table S2. Cardiac and vascular structural characteristics of the study participants without or 
with ≥5 g/m2.7 regression of LVMi or normalization of LVMi during follow-up 
Variables No LVMi 
reduction 
(N = 1684) 
LVMi 
reduction 
(n = 489) 
P-
value 
Carotid IMT max 1 (mm) 1.8 ±0.8 1.7 ±0.7 0.024 
LV Mass Index baseline (g/m2.7) 55.7± 6.4 58.0 ±10.0 <0.001 
Concentric baseline LV geometry (%) 15 21 0.001 
Concentric follow-up LV geometry (%) 14 7 <0.001 
e-GFR (mL/min/1.73 m2) 73± 17 75± 17 0.073 
Pulse Pressure / Stroke index (mmHg/mL×m-2.04) 2.14±0.63 2.06±0.59 0.008 
IMT: Intima media thickness; LV: Left ventricular; e-GFR: estimated glomerular filtration rate.
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Table S3. Blood pressure and distribution of antihypertensive medication among patients 
with or without ≥5 g/m2.7 regression of LVMi or normalization of LVMi during follow-up 
 No LVMi 
reduction 
(N = 1684) 
LVMi 
reduction 
(n = 489) 
P-Value 
Reduction in SBP during follow-up (mmHg) 8±16 12±17 <0.001 
Reduction in DBP during follow-up (mmHg) 6±10 10±10 <0.001 
Optimal BP control baseline (%) 48 46 0.608 
Optimal BP control during follow-up (%) 87 90 0.032 
Number of antihypertensive drugs 1.9± 1.1 1.9 ±1.0 0.653 
Beta-blocker (%) 28 24 0.035 
Ca-channel blockers (%) 32 30 0.432 
ACE* inhibitors (%) 41 41 0.977 
ARB ** (%) 35 38 0.226 
Diuretics (%) 53 54 0.586 
*ACE: Angiotensin converting enzyme 
** ARB: Angiotensin AT1 receptor blocker
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Table S4. Univariable and multivariable regression analysis of covariates associated with lack of LVMi reduction or normalization of LVH in 
treated hypertensive subjects. 
 Univariable Multivariable 
  Model 1 Model 2 
 OR 95%CI p OR 95%CI p OR 95%CI P 
Age (years) 1.03 1.02-1.04 <0.001 1.03 1.01-1.04 <0.001 1.03 1.02-1.04 <0.001 
Female sex 1.57 1.28-1.93 <0.001 2.22 0.99-1.57 0.060 1.39 0.98-1.57 0.072 
BP control (n/y) 0.67 0.50-0.97 0.033 0.52 0.35-0.75 0.001 0.53 0.37-0.78 0.010 
LVMi (g/m2.7) 0.96 0.95-0.98 <0.001 0.95 0.94-0.97 <0.001 0.95 0.94-0.97 <0.001 
Obesity (n/y) 1.50 1.22-1.86 <0.001 1.74 1.37-2.21 <0.001 1.78 1.40-2.26 <0.001 
Carotid IMT (mm) 1.32 1.14-1.52 <0.001 1.22 1.03-1.44 0.024 1.22 1.02-1.45 0.025 
Diabetes (n/y) 1.42 1.04-1.93 0.028       
Isolated systolic hypertension (n/y) 1.67 1.25-2.22 <0.001 1.81 1.29-2.54 0.001 1.76 1.25-2.48 0.001 
Duration of hypertension (years) 1.02 1.01-1.04 0.006       
Number of antihypertensive drugs 1.02 0.93-1.13 0.671    1.20 0.90-1.61 0.184 
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Follow-up time (years) 0.97 0.95-1.00 0.031       
Reduction in SBP (5 mmHg) 0.93 0.89-0.96 <0.001 0.96 0.92-0.99 0.034 0.95 0.91-0.99 0.021 
Reduction in DBP (5mmHg) 0.86 0.80-0.93 <0.001       
Beta-blocker 1.29 1.02-1.63 0.035    1.61 1.14-2.33 0.024 
Ca-channel blockers 1.09 0.89-1.36 0.432    1.41 0.98-2.04 0.288 
ACE inhibitors 1.00 0.81-1.22 0.977    1.14 0.87-1.47 0.351 
ARB 1.14 0.93-1.41 0.226    1.21 0.91-1.61 0.184 
Diuretics 1.05 0.86-1.30 0.586    1.09 0.72-1.64 0.702 
Model 1: including variables that were significant in univariable logistic analysis (in boldface). 
Model 2: also including number and class of medication forced into the Model 1. 
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